Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

Inclusion Criteria: * Written consent to participate in the study * Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions * Symptoms associated with OA of the knee for ≥ 6 months prior to Screening (patient reported is acceptable) * Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA * Index knee pain for \>15 days over the last month (as reported by the patient) * Body mass index (BMI) ≤ 40 kg/m2 * Ambulatory and in good general health Exclusion Criteria: * Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease * History of infection in the index knee joint * Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening * Presence of surgical hardware or other foreign body in the index knee * Unstable joint within 12 months of Screening * IA corticosteroid (investigational or marketed) in any joint within 6 months of Screening * IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening * Intravenous or Intramuscular corticosteroids (investigational or marketed) within 3 months of Screening * Oral corticosteroids (investigational or marketed) within 1 month of Screening * Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening * Any other IA investigational drug/biologic use within 6 months of Screening or 5 half-lives (whichever is longer) * Prior use of FX006 * Women of child-bearing potential not using effective contraception or who are pregnant or nursing